Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
14.47
+0.49 (3.51%)
Jul 1, 2025, 4:00 PM - Market closed
Viridian Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Viridian Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $38.5, which forecasts a 166.07% increase in the stock price over the next year. The lowest target is $27 and the highest is $61.
Price Target: $38.5 (+166.07%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 20, 2025.
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 6 | 6 | 5 |
| Hold | 3 | 3 | 3 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +148.79% | May 20, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $46 → $45 | Buy | Maintains | $46 → $45 | +210.99% | May 7, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $31 → $27 | Strong Buy | Maintains | $31 → $27 | +86.59% | May 7, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $42 → $38 | Buy | Maintains | $42 → $38 | +162.61% | May 7, 2025 |
| Needham | Needham | Strong Buy Maintains $38 → $36 | Strong Buy | Maintains | $38 → $36 | +148.79% | May 7, 2025 |
Financial Forecast
Revenue This Year
202.33K
from 302.00K
Decreased by -33.00%
Revenue Next Year
34.81M
from 202.33K
Increased by 17,102.33%
EPS This Year
-4.03
from -3.07
EPS Next Year
-3.88
from -4.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 863,100 | 96.9M | 428.4M | ||
| Avg | 202,327 | 34.8M | 247.3M | ||
| Low | n/a | n/a | 102.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 185.8% | 47,800.1% | 1,130.9% | ||
| Avg | -33.0% | 17,102.3% | 610.5% | ||
| Low | - | - | 195.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.41 | -2.99 | -1.07 | ||
| Avg | -4.03 | -3.88 | -2.10 | ||
| Low | -4.67 | -5.15 | -2.98 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.